Zelira Therapeutics Ltd has released a press release.
Hope 1 Longitudinal, Real-World Data Trial in ASD Results
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- March 2022 Quarterly Activities Report
- Appendix 4D & FY22 Interim Financial Report
- ZLD: Zelira to acquire Health House International Limited
- Zelira Therapeutics Ltd to acquire Health House
- December 2021 Quarterly Activities Report
Later from Zelira Therapeutics
- Zenivol Longitudinal, RWD Trial in Insomnia Results
- EDCDM Technology License Agreement Update
- Pause in Trading
- Response to ASX Price Query
- Zenivol receives formal BfArM approval in Germany
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics